GoldenGolden
Beijing Biocytogen Co., Ltd.

Beijing Biocytogen Co., Ltd.

Beijing Biocytogen Co is a biotechnology company and provider of antibody discovery, disease model, and preclinical testing services for research and drug development.

Beijing Biocytogen is a biotechnology company focused on antibody discovery, disease models, and preclinical testing. The company partners with research scientists in the biomedical industry to provide gene editing services, animal disease models, and antibody development services.

Timeline

September 15, 2020
Beijing Biocytogen Co., Ltd. raises a $150,000,000 series D round from 3E Bioventures Capital, Baidu Capital, CMB International Capital Corporation, Cowin Capital and SDIC Venture Capital.
August 8, 2019
Beijing Biocytogen Co., Ltd. raises a $84,000,000 series D round from 3E Bioventures Capital, CMB International Capital Corporation and SDIC Venture Capital.
April 10, 2018
Beijing Biocytogen Co., Ltd. raises a $63,400,000 series C round from 3E Bioventures Capital, CMB International Capital Corporation, Cowin Capital, Oriza Holdings and SDIC Venture Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Beijing Biocytogen Co., Ltd. Series D round, September 15, 2020
150,000,000
September 15, 2020
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.